ArticleInternational journal of clinical oncology2025

PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs; approval of belantamab mafodotin for multiple myeloma, asciminib for leukemia, osimertinib for lung cancer, amivantamab for lung cancer, and pembrolizumab for pleural mesothelioma in Japan.

Noriomi Matsumura et al.PubMed ↗Publisher ↗

No numbers read from the abstract.